Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IVAN EDUARDO CICHOWICZ

Allopathic & Osteopathic Physicians Psychiatry & Neurology Geriatric Psychiatry

NPI
1932312840
CMS profile
589106
Location
BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$66,255.29

197 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 4; records 1–50 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IVAN EDUARDO CICHOWICZ

NPI 1932312840 · CMS profile ID 589106

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Geriatric Psychiatry

BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 4; records 1–50 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932312840?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IVAN EDUARDO CICHOWICZ, NPI 1932312840, CMS profile ID 589106. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 4; records 1–50 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932312840?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). IVAN EDUARDO CICHOWICZ, NPI 1932312840, CMS profile ID 589106. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 4; records 1–50 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932312840?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
IVAN EDUARDO CICHOWICZ, NPI 1932312840, CMS profile ID 589106, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 4; records 1–50 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1932312840?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

197 matching records · $66,255.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 197 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 197.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $6.3012/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072813 CMS
AbbVie Inc. $12.2112/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996451677 CMS
Lundbeck LLC $21.9412/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032197143 CMS
AbbVie Inc. $14.4512/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996451673 CMS
Janssen Pharmaceuticals, Inc $33.5312/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072771 CMS
Janssen Pharmaceuticals, Inc $15.7212/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072783 CMS
Janssen Pharmaceuticals, Inc $9.1812/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072792 CMS
Janssen Pharmaceuticals, Inc $129.6612/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072801 CMS
ITI, Inc. $20.6312/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040498839 CMS
Otsuka America Pharmaceutical, Inc. $22.2812/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014278333 CMS
LivaNova USA, Inc. $24.4212/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043003501 CMS
Janssen Pharmaceuticals, Inc $3,510.0012/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072762 CMS
Supernus Pharmaceuticals, Inc. $24.5812/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053224867 CMS
Supernus Pharmaceuticals, Inc. $8.7611/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053224861 CMS
Alkermes, Inc. $22.8211/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022795417 CMS
Janssen Pharmaceuticals, Inc $38.9111/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072749 CMS
Janssen Pharmaceuticals, Inc $4,095.0011/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072729 CMS
Janssen Pharmaceuticals, Inc $3,510.0011/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072739 CMS
AbbVie Inc. $20.8711/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996451669 CMS
Otsuka America Pharmaceutical, Inc. $4.4711/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014278325 CMS
Janssen Pharmaceuticals, Inc $450.0011/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072331 CMS
Janssen Pharmaceuticals, Inc $4,095.0011/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072533 CMS
AbbVie Inc. $12.4411/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996451665 CMS
ITI, Inc. $23.0011/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040498831 CMS
ITI, Inc. $115.1711/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040498823 CMS
Janssen Pharmaceuticals, Inc $4,095.0011/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072453 CMS
Janssen Pharmaceuticals, Inc $4,095.0011/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072523 CMS
Janssen Pharmaceuticals, Inc $102.5811/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072859 CMS
Teva Pharmaceuticals USA, Inc. $12.1410/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056826589 CMS
Janssen Pharmaceuticals, Inc $11.6410/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072584 CMS
Janssen Pharmaceuticals, Inc $216.7310/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072595 CMS
Janssen Pharmaceuticals, Inc $167.9510/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072613 CMS
Janssen Pharmaceuticals, Inc $126.7810/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072721 CMS
Janssen Pharmaceuticals, Inc $119.5810/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072889 CMS
Janssen Pharmaceuticals, Inc $15.9510/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072544 CMS
Janssen Pharmaceuticals, Inc $23.9110/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072553 CMS
Janssen Pharmaceuticals, Inc $18.0510/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072565 CMS
Janssen Pharmaceuticals, Inc $5.6710/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072573 CMS
Janssen Pharmaceuticals, Inc $130.6010/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072603 CMS
Otsuka America Pharmaceutical, Inc. $18.3510/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014278319 CMS
Janssen Pharmaceuticals, Inc $619.0510/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072711 CMS
Janssen Pharmaceuticals, Inc $175.4910/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072413 CMS
Janssen Pharmaceuticals, Inc $177.5510/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072433 CMS
Janssen Pharmaceuticals, Inc $5.5010/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072473 CMS
Janssen Pharmaceuticals, Inc $167.9510/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072351 CMS
Janssen Pharmaceuticals, Inc $175.4910/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072373 CMS
Janssen Pharmaceuticals, Inc $52.8510/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072393 CMS
Janssen Pharmaceuticals, Inc $22.8410/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072403 CMS
Janssen Pharmaceuticals, Inc $177.5510/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072423 CMS
Janssen Pharmaceuticals, Inc $15.4510/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988072463 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23,469.29 98
PY2020 $10,926.30 70
PY2021 $12,526.57 88
PY2022 $21,308.64 81
PY2023 $66,255.29 197
PY2024 $32,766.53 124
PY2025 $87,533.38 171

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,956.10 109
PY2024 Principal investigator $75,358.86 60
PY2023 Principal investigator $161,875.94 49
PY2022 Principal investigator $105,783.26 41
PY2021 Principal investigator $38,926.54 20
PY2020 Principal investigator $8,150.00 1
PY2019 Recipient $1,498.98 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 LivaNova USA, Inc. $1,393.60 12/14/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942166399
Principal investigator 1 LivaNova USA, Inc. $1,100.00 12/13/2022 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 942174553
Principal investigator 1 LivaNova USA, Inc. $5,695.00 12/01/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942166379
Principal investigator 1 LivaNova USA, Inc. $65.00 11/29/2022 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 942173985
Principal investigator 1 LivaNova USA, Inc. $615.00 11/29/2022 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 942174201
Principal investigator 1 LivaNova USA, Inc. $1,219.40 11/22/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942166413
Principal investigator 1 LivaNova USA, Inc. $4,053.50 11/02/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942166385
Principal investigator 1 LivaNova USA, Inc. $1,299.80 10/26/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942166419
Principal investigator 1 LivaNova USA, Inc. $1,219.40 10/18/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942166407
Principal investigator 1 LivaNova USA, Inc. $2,599.60 10/12/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 942166393
Principal investigator 1 LivaNova USA, Inc. $1,031.80 09/28/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166631
Principal investigator 1 LivaNova USA, Inc. $5,259.50 09/20/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166315
Principal investigator 1 LivaNova USA, Inc. $335.00 09/09/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166309
Principal investigator 1 LivaNova USA, Inc. $272.56 09/09/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942166361
Principal investigator 1 LivaNova USA, Inc. $15,322.90 09/07/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166303
Principal investigator 1 LivaNova USA, Inc. $65.00 08/16/2022 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 942173765
Principal investigator 1 LivaNova USA, Inc. $3,738.60 07/27/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166329
Principal investigator 1 LivaNova USA, Inc. $272.56 07/27/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES LLC
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942166367
Principal investigator 1 LivaNova USA, Inc. $93.80 07/21/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166321
Principal investigator 1 LivaNova USA, Inc. $798.92 07/08/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942166355
Principal investigator 1 LivaNova USA, Inc. $1,139.00 06/30/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942166291
Principal investigator 1 LivaNova USA, Inc. $1,353.40 06/16/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942166283
Principal investigator 1 LivaNova USA, Inc. $9,112.00 06/09/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942166277
Principal investigator 1 LivaNova USA, Inc. $12,502.20 06/02/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942166265
Principal investigator 1 LivaNova USA, Inc. $4,060.20 05/05/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes No dispute reported 06/30/2026 942166271
Principal investigator 1 LivaNova USA, Inc. $10,291.20 03/31/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166251
Principal investigator 1 LivaNova USA, Inc. $65.00 03/22/2022 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 942173405
Principal investigator 1 LivaNova USA, Inc. $4,495.70 03/17/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166225
Principal investigator 1 LivaNova USA, Inc. $3,651.50 03/10/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166205
Principal investigator 1 LivaNova USA, Inc. $65.00 03/08/2022 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 942173246
Principal investigator 1 LivaNova USA, Inc. $93.80 03/03/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166193
Principal investigator 1 LivaNova USA, Inc. $2,338.30 02/23/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166237
Principal investigator 1 LivaNova USA, Inc. $475.00 02/22/2022 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 942173111
Principal investigator 1 LivaNova USA, Inc. $623.10 02/17/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166219
Principal investigator 1 LivaNova USA, Inc. $1,353.40 02/10/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166199
Principal investigator 1 LivaNova USA, Inc. $314.90 02/03/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166187
Principal investigator 1 LivaNova USA, Inc. $1,313.20 01/25/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166243
Principal investigator 1 LivaNova USA, Inc. $2,338.30 01/20/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166231
Principal investigator 1 LivaNova USA, Inc. $86.22 01/20/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166257
Principal investigator 1 LivaNova USA, Inc. $3,597.90 01/12/2022 Non-covered Recipient Entity
GLOBAL MEDICAL INSTITUTES FLORIDA LLC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 942166213
Principal investigator 1 LivaNova USA, Inc. $63.00 01/07/2022 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 942172927